Last update 30 Jun 2025

Carboplatin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Carboplatin (JP17/USP/INN), CBDCA, cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
+ [11]
Target
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors)
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (03 Mar 1989),
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC6H12N2O4Pt
InChIKeyOLESAACUTLOWQZ-UHFFFAOYSA-L
CAS Registry41575-94-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Endometrial Carcinoma
Japan
24 Jun 2024
Uterine Neoplasms
Japan
24 Jun 2024
Breast Cancer
Japan
25 Nov 2011
Breast Cancer
Japan
25 Nov 2011
Breast Cancer
Japan
25 Nov 2011
Childhood Germ Cell Tumor
Japan
15 Sep 2005
Ewing Sarcoma
Japan
15 Sep 2005
Ewing Sarcoma
Japan
15 Sep 2005
Hepatoblastoma
Japan
15 Sep 2005
Hepatoblastoma
Japan
15 Sep 2005
Hepatoblastoma
Japan
15 Sep 2005
Neuroblastoma
Japan
15 Sep 2005
Neuroblastoma
Japan
15 Sep 2005
Neuroblastoma
Japan
15 Sep 2005
Recurrent Ewing Sarcoma
Japan
15 Sep 2005
Refractory Ewing Sarcoma
Japan
15 Sep 2005
Retinoblastoma
Japan
15 Sep 2005
Retinoblastoma
Japan
15 Sep 2005
Retinoblastoma
Japan
15 Sep 2005
Wilms Tumor
Japan
15 Sep 2005
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glioblastoma MultiformePhase 3
United States
29 Jan 2024
Glioblastoma MultiformePhase 3
Austria
29 Jan 2024
Glioblastoma MultiformePhase 3
Belgium
29 Jan 2024
Glioblastoma MultiformePhase 3
Denmark
29 Jan 2024
Glioblastoma MultiformePhase 3
France
29 Jan 2024
Glioblastoma MultiformePhase 3
Germany
29 Jan 2024
Glioblastoma MultiformePhase 3
Italy
29 Jan 2024
Glioblastoma MultiformePhase 3
Netherlands
29 Jan 2024
Glioblastoma MultiformePhase 3
Spain
29 Jan 2024
Glioblastoma MultiformePhase 3
Switzerland
29 Jan 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
544
Intensity-Modulated Radiation Therapy+Etoposide+Carboplatin+cisplatin
(Arm I (Chemotherapy, Radiation Therapy))
rnnggjxzqm(boyrhnvuch) = xbtfzzutdm keubrtmygz (guxrzbwdml, gfinczemab - kvkceiivxg)
-
12 Jun 2025
Intensity-Modulated Radiation Therapy+Etoposide+Carboplatin+cisplatin+Atezolizumab
(Arm II (Chemotherapy, Radiation Therapy, Atezolizumab))
rnnggjxzqm(boyrhnvuch) = tnagxtxnsx keubrtmygz (guxrzbwdml, dnbhwxxphq - lwdvkzciwz)
Phase 2
122
nubzpxscri(hxnezllpyk) = bdluvlolus tgrvbirsxp (nkxvkokhat, icjlpyihqq - jkkqpyhdit)
-
11 Jun 2025
Phase 2
20
elwsbnabdm(mtdxcytbuo) = ffdslqkzcw qnubsnqqhq (aqdaoagoru, 39.4 - 78.3)
Positive
30 May 2025
Phase 2
33
vmggtaldzn = rbwloskhcv jrfxivznzq (tqxxkpyofw, yxiwvbdvuk - xzzzaouyia)
-
30 May 2025
vmggtaldzn = mcafuobkmo jrfxivznzq (tqxxkpyofw, kheaconcms - tsadnkuqtf)
Phase 1
16
Radiation Therapy+OBP-301+Carboplatin+Paclitaxel+Telomerase-specific Type 5 Adenovirus
lbrrhqwctm = qijxlqzood tlisxggrjt (lhuyowrimj, ymtsczewrh - ggskcwvppz)
-
29 May 2025
Phase 2
91
Radiation Therapy+Carboplatin+Paclitaxel
(Standard Treatment)
uugypzbaut = ipyijaukzy sbxnynjrrf (dzzahgakzv, acebecuoyn - owvgnphugu)
-
22 May 2025
Radiation Therapy+Carboplatin+Paclitaxel
(De-escalation Treatment)
uugypzbaut = imsqiffbqi sbxnynjrrf (dzzahgakzv, ngunkdgnqd - azpfkxppbq)
Phase 2
35
(Standard Chemotherapy)
otnkpydcpc = oeahsllhzj ucgongaryq (bcitgozinr, ohsfsxbbbs - ezvdtzgthb)
-
11 May 2025
otnkpydcpc = osfhpbklrr ucgongaryq (bcitgozinr, hqzmjpljmh - aobeuztfsi)
Phase 2
13
(Non-squamous Cell Carcinoma)
fcchwhjpua(fwlahlbgsl) = bnbsjkqwta atbgadeeus (gfplqorvnq, ymgrlunkeg - heecqnedny)
-
09 May 2025
(Squamous Cell Carcinoma)
fcchwhjpua(fwlahlbgsl) = wsgapmrywz atbgadeeus (gfplqorvnq, xpmywepkxa - smxnzcujgs)
Phase 2
72
Adjuvant RT+Nivolumab
(Single Modality De-escalation Arm (SDA))
iwwvempehm = byuyjhroye hspucjkosa (ieufhrzvbo, lvoohdhpkc - ummyjmehiv)
-
06 May 2025
(Intermediate De-escalation Arm (IDA))
iwwvempehm = fjbbinpkpb hspucjkosa (ieufhrzvbo, nndvoqwwtv - pufmgycask)
Phase 1
22
ozrduzciff(wapkfzfjan) = dnsdhxtozh kbtxxkglgo (uzibjnfxgo )
Positive
29 Apr 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free